Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02506907 · ClinicalTrials.gov registry record

Characterizing Hemodynamic Compensation in Patients With Intracranial Stenosis

A clinical trial, sponsored by Vanderbilt University.

Completed
Registry status
63
Enrollment target

NCT02506907 is a clinical trial that has completed, run by Vanderbilt University. The registered enrollment target is 63 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02506907 has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
63 participants
Enrollment target

Study Summary

The overall aim of this work is to assess the relationship between stroke risk and hemodynamic compensation strategies, as measured using a novel 3.0 Tesla MRI protocol, in patients with symptomatic intracranial (IC) steno-occlusive disease. Recent studies have shown high two-year ischemic stroke rates in symptomatic patients with IC arterial stenosis. Therapy for IC stenosis patients includes revascularization with angioplasty, IC stenting, or bypass, however identification of patients most likely to benefit from these more aggressive interventions, rather than medical management alone, has been problematic. Accurate measurements of hemodynamic compromise are likely required to better define stroke risk and guide treatment decisions. Specifically, in IC stenosis patients with compromised cerebral perfusion pressure (CPP), the extent of hemodynamic compromise reflects the autoregulatory capacity of vasculature to increase arterial cerebral blood volume (aCBV) and/or develop collaterals to supplement cerebral blood flow (CBF). The prevalence of CBF collateralization and aCBV autoregulation has been hypothesized to correlate uniquely with stroke risk, however the extent of this correlation has been debated. The critical barrier to stratifying stroke risk rests with a lack of (i) methodology for measuring multiple hemodynamic factors with high specificity and (ii) noninvasive approaches capable of monitoring longitudinal progression of impairment. The investigators have demonstrated the clinical utility of relatively new, noninvasive MRI approaches for assessing cerebrovascular reactivity (CVR), aCBV, and collateral CBF. The investigators hypothesize that stroke risk can be more completely evinced from collective measurements of these parameters. Therefore, the investigators propose to implement a novel, validated hemodynamic MRI protocol to assess tissue-level impairment and compensation strategies in patients with IC stenosis. Using a collective approach combining me

Trial Details

FieldValue
Enrollment Target 63 participants
Start Date 2012-08
Est. Completion 2017-11-01

Sponsor

Vanderbilt University

430 total trials

What the Registry Record Tells You About NCT02506907

The ClinicalTrials.gov registry entry for NCT02506907 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 63 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt University, which has 430 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT02506907 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT02506907 about?

NCT02506907 is a clinical study titled "Characterizing Hemodynamic Compensation in Patients With Intracranial Stenosis". The overall aim of this work is to assess the relationship between stroke risk and hemodynamic compensation strategies, as measured using a novel 3.0 Tesla MRI protocol, in patients with symptomatic intracranial (IC) steno-occlusive disease. Recent studies have shown high two-year ischemic stroke ra...

What is the current status of trial NCT02506907?

This trial is currently completed. The enrollment target is 63 participants. The study started on 2012-08. Estimated completion is 2017-11-01.

Who is sponsoring clinical trial NCT02506907?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.